Healthcare -
Biotechnology - NASDAQ - US
$ 1.33
-6.34 %
$ 41.7 M
Market Cap
-0.56
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Acrivon Therapeutics, Inc. Common Stock
| Net Income | -80.6 M |
| Depreciation & Amortization | 1.01 M |
| Capital Expenditures | -2.77 M |
| Stock-Based Compensation | 14.3 M |
| Change in Working Capital | 2.44 M |
| Others | 3.18 M |
| Free Cash Flow | -68.4 M |
Cash Flow
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (80.6) | (60.4) | (31.2) | (16.2) | (5.3) |
| Depreciation & Amortization | 1.0 | 0.5 | 0.4 | 37 K | 13 K |
| Deferred Income Tax | 0 | (3.6) | 0 | 0.3 | 71 K |
| Stock Based Compensation | 14.3 | 11.6 | 2.2 | 0.5 | 3 K |
| Other Operating Activities | (2.8) | 1.1 | 33 K | 1.1 | 2.1 |
| Change in Working Capital | 2.4 | 8.1 | (1.5) | 0.3 | 0.3 |
| Cash From Operations | (65.7) | (42.6) | (30.1) | (14.0) | (2.8) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | (2.8) | (1.3) | (2.2) | (0.2) | 15 K |
| Other Items | (49.0) | 52.0 | (139.5) | 0 | 0 |
| Cash From Investing Activities | (51.8) | 50.7 | (141.7) | (0.2) | 15 K |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 58 K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 51.0 | (1.6) | (2.7) | 112.2 | 2.8 |
| Cash From Financing Activities | 121.0 | (1.6) | 101.7 | 112.2 | 2.9 |
| CHANGE IN CASH | |||||
| Net Change In Cash | 3.6 | 6.5 | (70.1) | 98.0 | 71 K |
| FREE CASH FLOW | |||||
| Free Cash Flow | (68.4) | (43.9) | (32.3) | (14.2) | (2.8) |